Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(08): 617-620
DOI: 10.1590/0004-282X20160091
ARTICLES

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Satisfação e pontos de vista dos pacientes com esclerose múltipla em tratamento com drogas modificadoras da doença
Caroline Vieira Spessotto
1   Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;
2   Residência em Clínica Médica da Angiocorpore, Santos SP, Brasil;
,
Hanaie Cavalli
3   Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
,
Audred Cristina Biondo Eboni
4   Centro Hospitalar Unimed, Joinville SC, Brasil;
,
Rafael Berlezi Machado
5   Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
,
Analara Munardi Mousquer
6   Universidade Regional de Blumenau, Blumenau SC, Brasil.
,
Lara Both Palazzo
5   Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
,
Alessandro Finkelsztejn
5   Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
,
Marcus Vinicius Magno Goncalves
4   Centro Hospitalar Unimed, Joinville SC, Brasil;
,
Henry Koiti Sato
3   Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
,
Fabio Siquineli
6   Universidade Regional de Blumenau, Blumenau SC, Brasil.
,
Yara Dadalti Fragoso
1   Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Objective The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients’ satisfaction with the treatment must be taken into consideration.

Methods Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs.

Results One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability.

Conclusion Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.

RESUMO

Objetivo O tratamento da esclerose múltipla (EM) com drogas-modificadoras-da-doença (DMDs) está evoluindo e novas drogas estão sendo comercializadas. Eficácia e segurança são aspectos cruciais nas medicações, porém a satisfação do paciente com o tratamento deve ser levada em consideração.

Métodos Entrevista individual com pacientes com EM investigando a satisfação e ponto de vista desta população em relação ao tratamento com DMDs.

Resultados Cento e vinte e oito pacientes atendidos em unidades especializadas de EM de cinco cidades diferentes foram entrevistados. Mais de 80% dos pacientes estava bastante satisfeito com as medicações utilizadas, considerando aspectos de conveniência de uso e benefício das drogas. O único aspecto que pontuou menos foi tolerabilidade.

Conclusão Parâmetros para melhor tratamento de EM devem incluir eficácia, segurança e satisfação dos pacientes com a DMD prescrita.

multiple sclerosis - glatiramer acetate - interferon-beta - natalizumab - fingolimod hydrochloride
esclerose múltipla - acetato de glatiramer - interferon beta - natalizumab - cloridrato de fingolimode


Publication History

Received: 12 January 2016

Accepted: 08 June 2016

Article published online:
06 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Hildebrandt H, Eling P. A longitudinal study on fatigue, depression, and their relation to neurocognition in multiple sclerosis. J Clin Exp Neuropsychol. 2014;36(4):410-7. doi:10.1080/13803395.2014.903900
  • 2 Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin. 2007;23:1209-15. doi:10.1185/030079907X188125
  • 3 Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24-40. doi:10.18553/jmcp.2013.19.s1.S24
  • 4 Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14(9):1029-42. doi:10.1586/14737175.2014.945523
  • 5 Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015;4(1):75-82. doi:10.1016/j.msard.2014.09.214
  • 6 Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17(2)74-82. doi:10.7224/1537-2073.2013-053
  • 7 Utz KS, Hoog J, Wentrup A, Berg S, Lämmer A, Jainsch B et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disorder. 2014;7(6):263-75. doi:10.1177/1756285614555335